VBI Vaccines Inc (NASDAQ:VBIV)
| 2.82 Delayed Data As of Apr 09 |  -0.05 / -1.74%Today’s Change | 0.87 Today|||52-Week Range 6.93 | +2.55% Year-to-Date |
Latest VBIV News | Press Releases
| Dynavax (DVAX) Up on Positive COVID-19 Vaccine Study Data (Revised) Apr 09 / Zacks.com - Paid Partner Content | Dynavax (DVAX) Up on Positive COVID-19 Vaccine Study Data Apr 07 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 2.87 |
| Today’s open | 2.85 |
| Day’s range | 2.80 - 2.93 |
| Volume | 3,180,931 |
| Average volume (3 months) | 6,926,050 |
| Market cap | $792.5M |
Data as of 04/09/2021
Growth & Valuation
| Earnings growth (last year) | +53.85% |
| Earnings growth (this year) | -28.57% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -52.23% |
| P/E ratio | -- |
| Price/Sales | 565.73 |
| Price/Book | 4.49 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| ZIOPZIOPHARM Oncology In... | -0.07 | -2.06% |
| HARPHarpoon Therapeutics... | +0.06 | +0.27% |
| CGENCompugen Ltd | 0.00 | 0.00% |
| VXRTVaxart Inc | -0.14 | -2.47% |
Data as of 04/09/2021
Financials
| Next reporting date | May 13, 2021 |
| EPS forecast (this quarter) | -$0.06 |
| Annual revenue (last year) | $1.1M |
| Annual profit (last year) | -$46.2M |
| Net profit margin | -4,357.21% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Cambridge, Massachusetts |
Forecasts
Chart unavailable
